CN107648231B - 右兰索拉唑药物制剂 - Google Patents
右兰索拉唑药物制剂 Download PDFInfo
- Publication number
- CN107648231B CN107648231B CN201610592697.5A CN201610592697A CN107648231B CN 107648231 B CN107648231 B CN 107648231B CN 201610592697 A CN201610592697 A CN 201610592697A CN 107648231 B CN107648231 B CN 107648231B
- Authority
- CN
- China
- Prior art keywords
- parts
- enteric
- pellets
- release
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 title claims abstract description 63
- 229960003568 dexlansoprazole Drugs 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title abstract description 33
- 239000008188 pellet Substances 0.000 claims abstract description 162
- 239000003814 drug Substances 0.000 claims abstract description 98
- 229940079593 drug Drugs 0.000 claims abstract description 61
- 230000003111 delayed effect Effects 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims abstract description 30
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims abstract description 29
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims abstract 4
- 238000000576 coating method Methods 0.000 claims description 99
- 239000011248 coating agent Substances 0.000 claims description 96
- 239000010410 layer Substances 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 238000001035 drying Methods 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 37
- 238000005516 engineering process Methods 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 33
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 28
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 28
- 229930006000 Sucrose Natural products 0.000 claims description 28
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 28
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 28
- 238000005507 spraying Methods 0.000 claims description 26
- 239000005720 sucrose Substances 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 23
- 238000005469 granulation Methods 0.000 claims description 16
- 230000003179 granulation Effects 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 16
- 239000001095 magnesium carbonate Substances 0.000 claims description 16
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 9
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 239000012055 enteric layer Substances 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000001069 triethyl citrate Substances 0.000 claims description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013769 triethyl citrate Nutrition 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 229940116364 hard fat Drugs 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims 4
- 239000008213 purified water Substances 0.000 claims 4
- 229960004793 sucrose Drugs 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 water Chemical compound 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 abstract description 13
- 238000002156 mixing Methods 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 238000012423 maintenance Methods 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- 238000007873 sieving Methods 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 14
- 239000000853 adhesive Substances 0.000 description 10
- 230000001070 adhesive effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000012216 screening Methods 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940008871 dexilant Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007963 capsule composition Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010063655 Erosive oesophagitis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610592697.5A CN107648231B (zh) | 2016-07-25 | 2016-07-25 | 右兰索拉唑药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610592697.5A CN107648231B (zh) | 2016-07-25 | 2016-07-25 | 右兰索拉唑药物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107648231A CN107648231A (zh) | 2018-02-02 |
CN107648231B true CN107648231B (zh) | 2021-07-16 |
Family
ID=61127124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610592697.5A Active CN107648231B (zh) | 2016-07-25 | 2016-07-25 | 右兰索拉唑药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107648231B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113842371A (zh) * | 2021-10-11 | 2021-12-28 | 江苏集萃新型药物制剂技术研究所有限公司 | 一种双相释药组合物、双相释药固体药剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884629A (zh) * | 2002-10-16 | 2010-11-17 | 武田药品工业株式会社 | 控释制剂 |
CN103381268A (zh) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN105769824A (zh) * | 2014-12-16 | 2016-07-20 | 四川海思科制药有限公司 | 一种兰索拉唑缓释胶囊及其制备方法 |
CN105997883A (zh) * | 2016-05-06 | 2016-10-12 | 杭州容立医药科技有限公司 | 一种固体分散体及其制备方法和应用 |
-
2016
- 2016-07-25 CN CN201610592697.5A patent/CN107648231B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101884629A (zh) * | 2002-10-16 | 2010-11-17 | 武田药品工业株式会社 | 控释制剂 |
CN103381268A (zh) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN105769824A (zh) * | 2014-12-16 | 2016-07-20 | 四川海思科制药有限公司 | 一种兰索拉唑缓释胶囊及其制备方法 |
CN105997883A (zh) * | 2016-05-06 | 2016-10-12 | 杭州容立医药科技有限公司 | 一种固体分散体及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
Novel Lansoprazole-Loaded Nanoparticles for the Treatment of Gastric Acid Secretion-Related Ulcers: In Vitro and In Vivo Pharmacokinetic Pharmacodynamic Evaluation;Milind Alai等;《The AAPS Journal》;20140212;第16卷(第3期);361-372 * |
右旋兰索拉唑脉冲肠溶胶囊的制备;王雄飞等;《中国医药工业杂志》;20160420;第47卷(第4期);433-437 * |
Also Published As
Publication number | Publication date |
---|---|
CN107648231A (zh) | 2018-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007276874B2 (en) | Granular pharmaceutical compositions | |
AU737121B2 (en) | Tramadol multiple unit formulations | |
CN1886119B (zh) | 泮托拉唑多颗粒制剂 | |
RU2490012C2 (ru) | Системы доставки лекарственного средства, содержащие слабощелочной селективный 5-ht3, серотониновый блокатор и органические кислоты | |
JP2001526213A (ja) | 経口医薬パルス放出剤形 | |
KR102391496B1 (ko) | 탐수로신 염산염 함유 서방성 펠렛을 포함하는 용출률이 제어된 경구투여용 약제학적 제제 | |
JP2008519070A (ja) | プロトンポンプ阻害剤用の新規な改変された放出の錠剤製剤 | |
JP2012107048A (ja) | 時限拍動性薬物送達システム | |
JPS61501151A (ja) | 拡散被覆された複合単位服用剤 | |
AU5791900A (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
US20080139624A1 (en) | Oral Dosage Form Comprising Rosiglitazone | |
JP2023026623A (ja) | エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤 | |
JP2008534681A (ja) | ジピリダモール持続放出製剤及びそれを調製のための方法 | |
US20230000780A1 (en) | Dosage form comprising an alkaline agent and an enteric coating layer | |
WO2007102714A1 (en) | Safe controlled release preparation composition containing zolpidem or its salt | |
CN107648231B (zh) | 右兰索拉唑药物制剂 | |
WO2009006299A2 (en) | Multi-particulate systems | |
KR102290295B1 (ko) | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 | |
US20100080846A1 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
CN110946845A (zh) | 一种右旋雷贝拉唑钠缓释胶囊及其制备方法 | |
EP4072532B1 (en) | Dosage form for use in treating or preventing of a disease | |
EP3380084B1 (en) | Omeprazole formulations | |
KR100505898B1 (ko) | 철분함유 고밀도 펠렛 조성물 및 이의 제조방법 | |
Robota et al. | Polymethacrylates for Modified‐Release Formulations | |
US20110229530A1 (en) | Pharmaceutical dosage forms for time-specific drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug formulation of dexamethasone Effective date of registration: 20231117 Granted publication date: 20210716 Pledgee: Industrial and Commercial Bank of China Limited Lianyungang Economic and Technological Development Zone sub branch Pledgor: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2023980066019 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210716 Pledgee: Industrial and Commercial Bank of China Limited Lianyungang Economic and Technological Development Zone sub branch Pledgor: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2023980066019 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |